The central hypothesis is deceptively simple. FOXP3, best known as the master regulator of regulatory T cells, also acts inside tumor cells themselves, where it binds directly to the promoter of CD274, the gene encoding programmed death-ligand 1, or PD-L1, and represses its transcription. When FOXP3 can reach the promoter, PD-L1 expression is held in check. Venkatesan hypothesized that gain-of-function mutant p53, the kind of p53 mutation that does not merely disable the protein but arms it with new oncogenic activities, might bind FOXP3 directly and sequester it away from DNA. Stripped of its transcriptional regulator, the CD274 promoter would be left unguarded, allowing PD-L1 to accumulate on the tumor cell surface and blunt the effect of PD-1/PD-L1 blockade antibodies.

To test this idea computationally, the study first turned to clinical reality. Across three independent lung adenocarcinoma cohorts, the Cancer Genome Atlas PanCancer Atlas with 510 patients, the Singapore-based OncoSG cohort with 181 patients, and the Clinical Proteomic Tumor Analysis Consortium cohort with 110 patients, for a combined total of 670 individuals, the author asked whether disruption of the FOXP3-PD-L1 axis predicted patient outcomes. It did, and strongly. Patients whose tumors showed a broken FOXP3-PD-L1 relationship had significantly inferior overall survival, with a log-rank p-value of 6 × 10⁻⁴ and a hazard ratio of 1.48, meaning a 48 percent increase in the risk of death, with a 95 percent confidence interval running from 1.12 to 1.95. The association held across cohorts that differ in ancestry, treatment patterns, and genomic profiling methods, lending epidemiological weight to what is otherwise a purely theoretical construct at this stage.

The next layer of evidence concerned the DNA itself. Using the FIMO motif-scanning tool with the JASPAR 2024 position weight matrix for FOXP3, the study identified eight candidate FOXP3 consensus binding motifs, each matching the sequence GTAAACA, along the CD274 promoter, a result significant at a p-value of 7.93 × 10⁻⁵. These are the positions where FOXP3 would be expected to dock if it were free to do so. Importantly, the author is explicit that these candidate sites await confirmation by chromatin immunoprecipitation sequencing, the gold-standard experimental technique for mapping where a transcription factor actually sits on the genome. The motifs establish plausibility, not proof.

Chromatin accessibility added a crucial element of biological specificity. Analysis of ATAC-seq data, which measures how open and transcriptionally permissive regions of the genome are, revealed that the CD274 promoter is restricted, or physically less accessible, in lung adenocarcinoma but not in head and neck squamous cell carcinoma. This lineage-specific pattern matters because it begins to explain a long-standing puzzle: why PD-L1 dysregulation tied to p53 mutation appears to behave differently in different tumor types. A mechanism that depends on chromatin context rather than on mutation status alone could account for the fact that the FOXP3-checkpoint uncoupling observed in a companion pan-cancer analysis was present in 67 percent of adenocarcinomas but in exactly zero percent of non-adenocarcinoma tumors among 4,205 samples drawn from eight TCGA cohorts.

The structural heart of the study lies in its protein modeling. Using AlphaFold 3, the deep-learning system from Google DeepMind that predicts the structures of protein complexes, the author modeled a heterodimer between mutant p53 and FOXP3. The predicted interface showed confident local geometry, with predicted local distance difference test scores above 70 at the contact region, indicating that the model considers the physical association well supported at the residue level. Predicted aligned error analysis, which estimates the reliability of relative domain placements, further supported the plausibility of a stable complex rather than a chance collision of two unrelated proteins.

Structure alone, however, says nothing about stability in the crowded, thermal environment of a living cell. To address that, the study turned to classical molecular dynamics. The predicted complex was solvated in a TIP3P water model and simulated with the AMBER ff19SB force field under physiological conditions: an isobaric-isothermal ensemble at 310 kelvin, a salt concentration of 0.15 molar sodium chloride, run for 2 nanoseconds on an NVIDIA A100 graphics processing unit. Over the course of the simulation, the complex underwent progressive compaction, with the radius of gyration contracting from 46.7 to 43.9 angstroms, a sign that the two chains were folding into one another rather than drifting apart. Correlated motion analysis showed significant inter-chain coordination, meaning the two proteins moved as a single mechanical unit, and root-mean-square fluctuation analysis of the interface residues between positions 150 and 300 revealed rigid geometry in the 1 to 2 angstrom range. The estimated interaction energy of the complex was −55.33 kilocalories per mole, a substantially favorable figure consistent with a stable physical association.

The final strand of evidence, drawn from a previously published preprint cited within the study, connects the structural story back to gene expression in real tumors. Among 517 TCGA lung adenocarcinoma samples, mutant p53 status was associated with significant upregulation of CD274, with a log2 fold change of 0.53 and an adjusted p-value below 0.0001, while FOXP3 expression itself was untouched, with a log2 fold change of just 0.014 and an adjusted p-value of 0.889. That dissociation is exactly what the sequestration model predicts: if mutant p53 were simply reducing FOXP3 production, FOXP3 mRNA would fall alongside rising PD-L1. Instead, FOXP3 remains present but appears functionally sidelined, unable to reach its target promoter and do its repressive work.

Taken together, the six layers of evidence form a coherent, if still provisional, narrative. Gain-of-function mutant p53, one of the most common molecular lesions in lung adenocarcinoma, may act as a molecular decoy for FOXP3, occupying it in the nucleoplasm and preventing promoter occupancy at eight candidate sites on CD274. The consequence is unrestrained PD-L1 expression, impaired immune surveillance, and measurably worse survival across 670 patients. Because the effect appears confined to adenocarcinoma lineages, the model also offers a testable explanation for why checkpoint therapy outcomes differ so markedly between lung adenocarcinoma and squamous histologies.

The author and the field alike are careful to emphasize what the study does not yet show. Computational prediction, however multi-layered, is not experimental demonstration. The critical missing pieces are co-immunoprecipitation experiments to confirm that mutant p53 and FOXP3 physically associate in cells, ChIP-seq to confirm FOXP3 occupancy loss at the CD274 promoter, and promoter reporter assays to show that FOXP3-mediated repression of CD274 is relieved by mutant p53 in a dose-dependent fashion. Until those experiments are done, the mutp53-FOXP3 interaction remains a candidate mechanism, albeit one supported by an unusually broad convergence of independent data types.

If validation succeeds, the therapeutic implications could be considerable. The mutp53-FOXP3 interface would become a high-priority drug target, and restoring FOXP3 access to the CD274 promoter, whether by disrupting the sequestration interaction or by designing combination regimens around it, could convert a subset of immunotherapy-resistant lung adenocarcinoma patients into responders. The study also underscores a broader lesson for computational oncology: when survival statistics, chromatin accessibility, structural prediction, and molecular dynamics all point in the same direction, even a single-author, unfunded effort conducted on cloud computing resources can generate hypotheses worthy of the laboratory’s full attention. For now, the mutant p53-FOXP3 axis stands as one of the most intriguing candidates yet proposed for explaining why so many lung cancer patients do not benefit from the immunotherapy revolution.

Natural killer cells are the sentinels of the innate immune system. Unlike T cells, which require prior exposure to a target and the presentation of antigens through specialized surface molecules, NK cells can recognize stressed, infected, or malignant cells on first contact and kill them within hours. This capacity makes them central to the body’s frontline defense against cancer, a process known as cancer immune surveillance. Yet tumors frequently persist and spread despite the presence of abundant NK cells in circulation, and one of the enduring mysteries of tumor immunology is precisely why these lethal cells appear to stand down in cancer patients.

The new research points to an unexpected answer that lies not in the proteins NK cells produce, but in a layer of gene regulation that operates above the genome’s protein-coding instructions. Long non-coding RNAs, or lncRNAs, are RNA transcripts longer than 200 nucleotides that are not translated into proteins but instead act as master regulators of gene expression. Many of them guide chemical modifications to DNA and histones, sculpt the three-dimensional architecture of chromatin, and determine which stretches of the genome are silenced or activated. In recent years, evidence has mounted that NK cell development, maturation, and cytotoxic function are all governed in part by these epigenetic mechanisms, making lncRNAs a compelling place to look for the origins of NK cell dysfunction in cancer.

To investigate, the research team — Mona Rady, Eman Mohamed, Ola Khorshid, and Khaled Abou-Aisha — isolated NK cells from the peripheral blood of patients with invasive breast cancer and from healthy donors, then systematically measured the expression of 84 carefully selected lncRNAs using a quantitative PCR array platform. This technique relies on the reverse transcription of RNA into complementary DNA followed by real-time amplification, allowing researchers to quantify transcript abundance with exquisite sensitivity. Expression differences between patient and control samples were calculated using the standard comparative threshold cycle method, which converts the difference in amplification kinetics between groups into a fold change in expression.

The results were unambiguous. Of the 84 lncRNAs profiled, 26 were significantly dysregulated in the NK cells of breast cancer patients. Ten genes showed significant downregulation, while 16 were significantly upregulated. Among the downregulated transcripts with known biological functions, the losses were dramatic. TSIX, a non-coding RNA intimately involved in regulating the X chromosome, was reduced to just 5 percent of its normal expression level, representing a fold change of 0.05 with a P value of 0.0037. CCAT1, a transcript implicated in chromatin organization and cancer biology, fell to 9 percent of control levels. XIST, the master orchestrator of X chromosome inactivation, dropped to 42 percent, and PTENP1-AS, an antisense transcript connected to the PTEN tumor suppressor axis, was reduced to 27 percent of its expression in healthy NK cells.

The upregulated side of the ledger was equally striking, and in one case extraordinary. CDKN2B-AS1, also known as ANRIL, a lncRNA that regulates the INK4b-ARF-INK4a tumor suppressor locus through chromatin remodeling, was expressed at more than 80 times its normal level, with a fold change of 81.80 and a P value of 0.0087. MEG3, a transcript involved in genomic imprinting and growth control, was elevated nearly 47-fold. HOTAIR, one of the most notorious lncRNAs in cancer research because of its role in reprogramming chromatin states and promoting metastasis, was increased almost 7-fold. AIRN, an imprinting-associated transcript, rose nearly 8-fold, and GNAS-AS1 was elevated more than 5-fold.

To make sense of these expression shifts, the researchers performed gene ontology and functional enrichment analysis, a computational approach that asks whether groups of altered genes share common biological roles more often than would be expected by chance. The analysis revealed coherent functional themes. The downregulated lncRNAs were significantly enriched in biological processes including chromatin organization, epigenetic regulation of gene expression, and dosage compensation through X chromosome inactivation. The upregulated lncRNAs converged on a complementary but distinct set of processes: epigenetic regulation, genomic imprinting, and chromatin remodeling. In other words, the entire epigenetic control apparatus of the NK cell appears to be rewired in breast cancer, with some regulatory programs collapsing and others running into overdrive.

Statistical rigor was central to the study’s design. Enrichment findings were validated using the Bonferroni correction, the most conservative method for controlling false positives in multiple testing, and differential expression significance was assessed using the two-stage step-up method of Benjamini, Krieger, and Yekutieli to calculate false discovery rate-adjusted q-values, with the significance threshold set at 10 percent. This approach, the authors explain, strikes a deliberate balance between stringency and statistical power, controlling the risk of chasing genes that appear dysregulated by chance alone while preserving the ability to detect genuine biological differences. Individual transcript comparisons were further evaluated with one-sample t-tests, and only transcripts meeting thresholds of at least a two-fold change in expression and statistically significant FDR-adjusted P values were considered dysregulated.

The visualization of the data reinforces the strength of the signal. A heatmap generated with the pheatmap package in R displays the average negative delta Ct values across patient and control groups without clustering, using a blue-white-red color gradient in which blue indicates lower expression and red indicates higher expression. Because the heatmap preserves true expression values rather than applying row-wise scaling, the color differences reflect genuine magnitude differences between groups rather than artifacts of normalization. A companion volcano plot plots the log2 fold change of all 84 lncRNAs against the negative logarithm of adjusted P values, with red dots marking upregulated transcripts and blue dots marking downregulated ones, while a bar chart of log-transformed relative expression values, complete with significance annotations, offers a clear view of the direction and size of each significant change.

What makes these findings potentially viral in their implications is the identity of the RNAs involved. HOTAIR and CDKN2B-AS1 are not obscure transcripts; they are pillars of cancer epigenetics literature, best known for their roles inside tumor cells, where they silence tumor suppressor programs and promote invasion. Finding them massively overexpressed inside immune cells — specifically inside the cytotoxic lymphocytes tasked with eliminating tumors — suggests that tumors may not merely escape NK cells by hiding from them, but may actively corrupt the internal regulatory machinery of their would-be executioners. Circulating factors such as tumor-derived extracellular vesicles, cytokines, and metabolites are known to travel through the bloodstream, and lncRNAs are increasingly recognized as molecules that can be shuttled between cells and can reprogram recipient cell behavior.

Likewise, the collapse of XIST and TSIX expression raises provocative questions about X chromosome dosage regulation in immune cells. Proper X inactivation is essential for gene dosage balance, and disruption of this process in NK cells could alter the expression of dozens of X-linked genes, including immune receptors and signaling molecules that govern NK cell activation and tolerance. Similarly, the downregulation of PTENP1-AS hints at perturbation of PTEN-linked signaling, a pathway central to cell survival, metabolism, and cytotoxic function in lymphocytes.

The researchers are careful to note that this study establishes correlation, not causation. The measurements were performed on circulating NK cells, and it remains to be demonstrated whether these lncRNA changes cause NK cell dysfunction or are a consequence of the tumor-bearing state. Nor is it yet clear whether the dysregulation is reversible. But the therapeutic horizon is tantalizing. LncRNAs are tractable targets for antisense oligonucleotides and small interfering RNA technologies, both of which have advanced rapidly in clinical development. If specific lncRNAs prove to be drivers of NK cell exhaustion or suppression in breast cancer, restoring their normal expression could rejuvenate the anti-tumor activity of a patient’s own immune system, potentially in combination with existing NK cell-based therapies or checkpoint inhibitors.

The study also adds breast cancer to a growing list of malignancies in which immune cell lncRNA profiles diverge dramatically from healthy states, reinforcing the idea that cancer is a disease of the entire tumor ecosystem, not just the malignant cells themselves. With more than 2 million new breast cancer cases diagnosed globally each year, and with NK cells emerging as a major platform for next-generation cancer immunotherapy, understanding the RNA-level circuitry that governs NK cell behavior could prove decisive. This work, by mapping 84 regulatory transcripts and pinpointing 26 that go awry, provides both a hypothesis-generating atlas and a set of concrete molecular targets for the next generation of investigations into why the immune system’s most rapid killers fall silent in the face of cancer.

The research began with a question that has become increasingly important in cancer biology: why do apparently ordinary cells surrounding a tumor so often predict how aggressively the disease will progress? Fibroblasts are connective-tissue cells that help organize and maintain organs, repair injuries, and produce components of the extracellular matrix, the intricate protein scaffold surrounding cells. Inside tumors, however, fibroblasts can be reprogrammed into cancer-associated fibroblasts, or CAFs. Rather than behaving as passive structural support, these cells can remodel tissue, influence blood vessels, alter cancer-cell growth, and regulate immune activity. Much of the detailed work on CAFs has focused on pancreatic cancer, but their roles in lung cancer have been less completely understood. Columbia researchers therefore examined lung-tumor fibroblasts at the level of individual cells, looking for subtle molecular differences that would be hidden in an averaged tissue sample.

To perform that analysis, the team used single-cell transcriptomic profiling, a technique that measures patterns of gene activity in thousands of individual cells. Every cell contains essentially the same DNA, but different cell types activate different subsets of genes, creating distinctive molecular signatures. By sequencing messenger RNA from individual fibroblasts, scientists can determine which genes are switched on and group cells according to their functional programs. This approach is particularly powerful in tumors, where malignant cells, immune cells, blood-vessel cells, and connective-tissue cells coexist in constantly changing states. In the mouse model of lung cancer, the analysis revealed a fibroblast population that had not been recognized in healthy lung tissue. These cells expressed CHL1, a gene not normally associated with fibroblasts in the un diseased organ, providing a molecular marker for tracking the newly defined population.

Further experiments showed that CHL1-positive fibroblasts were not simply bystanders in the tumor microenvironment. They were positioned in a way that enabled them to influence the distribution of regulatory T cells, commonly known as Tregs. Tregs are essential immune regulators. They restrain potentially damaging immune reactions and help prevent the body from attacking its own tissues. In the lungs, this function is especially important because the organ is constantly exposed to airborne particles, microbes, and environmental antigens. Without effective immune braking, each breath could provoke inflammation. Cancer exploits that protective system. When Tregs accumulate near a tumor, they can suppress the activity of cytotoxic T cells and other immune mechanisms capable of recognizing and killing cancer cells. The newly identified fibroblasts therefore appear to convert a normal tissue-protection program into a localized shield for malignant cells.

The molecular connection between the fibroblasts and the Tregs involved a signaling protein called CXCL9. Chemokines such as CXCL9 act like molecular guidance cues, creating signals that influence the movement and positioning of immune cells. The Columbia team found evidence that the CHL1-positive fibroblasts use CXCL9 to recruit regulatory T cells to the edge of lung tumors. That location may be strategically important: the tumor border is where immune cells encounter cancer-associated signals and where the balance between attack and tolerance can determine whether malignant cells are contained or allowed to expand. In the mouse experiments, genetically disrupting components of this signaling system reduced the accumulation of Tregs around tumors. With fewer regulatory cells present, immune activity against the cancer increased and tumor control improved. The results suggest that the fibroblast–CXCL9–Treg pathway is not merely correlated with immune suppression but contributes directly to the tumor’s ability to resist immune elimination.

The discovery also highlights why cancer immunotherapy cannot be understood by studying immune cells alone. Treatments that activate T cells may fail when the surrounding tissue continually instructs those cells to remain inactive. Fibroblasts can provide that instruction through chemokines, matrix proteins, growth factors, and contact-dependent signals. In this case, the cancer-associated fibroblast population appears to create an immunological compartment in which suppressive T cells are concentrated and potentially supported. Blocking the pathway could therefore complement existing therapies by changing the physical and chemical environment around the tumor. The researchers emphasize that the findings do not yet constitute a treatment for patients. The experiments were performed in mouse models and through analyses of human tumor samples, and additional work will be needed to determine whether CXCL9 or CHL1 can be safely targeted without disrupting the immune regulation required for healthy lung function.

Evidence that the same fibroblasts occur in human disease came from tumor specimens and clinical information held in Columbia’s tissue bank. In human lung cancers, tumors containing greater numbers of CHL1-positive fibroblasts showed weaker immune responses and were associated with shorter progression-free survival. Progression-free survival measures how long patients live without their disease worsening, making the association clinically meaningful even though it does not by itself prove causation. The human observations align with the mouse experiments, in which disruption of the relevant signaling pathway reduced Treg accumulation and permitted stronger antitumor immunity. Together, the results suggest that CHL1-positive fibroblasts could serve as a biomarker identifying tumors with a particularly suppressive microenvironment. They might also help researchers select patients for future therapies designed to block Treg recruitment or dismantle the cellular structures that support immune escape.

One of the most intriguing questions is how these cells arise. The CHL1-positive fibroblasts were not detected as a normal fibroblast population in healthy lungs, raising the possibility that they are produced when existing stromal cells are transformed by signals from the developing tumor. Cancer cells, inflammatory molecules, low oxygen levels, and mechanical changes in the tissue can all alter fibroblast behavior. A normal fibroblast exposed to that combination may change its gene expression and acquire a new identity, including the ability to produce chemokines that reshape local immunity. If researchers can identify the signals that trigger this transformation, it may become possible to prevent the protective niche from forming before it is fully established. Such an approach could be different from directly killing tumor cells: instead, it would remove the support system that allows them to remain hidden.

The study adds to a growing picture of lung cancer as an ecosystem rather than a mass of malignant cells acting alone. Tumors survive through interactions with blood vessels, connective tissue, immune populations, and the biochemical environment surrounding them. The newly described fibroblasts demonstrate how a rare or previously overlooked cell state can have an outsized effect by organizing other cells in the tumor neighborhood. Their discovery was made possible by single-cell technology, but the broader challenge is now to translate a molecular signature into a practical intervention. Future studies will need to determine whether CHL1-positive fibroblasts are present across different lung-cancer subtypes, whether their abundance changes during treatment, and whether targeting CXCL9 affects the effectiveness or toxicity of immunotherapy. For now, the work offers a compelling explanation for one route by which lung tumors evade immune attack—and identifies a hidden cellular accomplice that may be vulnerable to precision treatment.

Colorectal cancer is diagnosed in approximately 55,000 people in Germany each year. Around one quarter of these cancers arise from serrated lesions, a distinctive type of colorectal polyp that can serve as a precursor to malignancy. Many of these lesions carry activating mutations in the BRAF gene. Although BRAF mutations are also found in other cancers, their presence in serrated colorectal lesions is associated with a tumor subtype that often develops aggressive biological features and responds poorly to available treatments. The molecular events that convert these precursor lesions into invasive cancer, however, have remained incompletely understood.

The new study places WNT signaling at the center of this transformation. WNT proteins regulate a fundamental communication network involved in cell proliferation, tissue organization, stem-cell maintenance, and embryonic development. In healthy intestinal tissue, WNT activity is carefully controlled because the pathway helps maintain the rapidly renewing lining of the gut. When this signaling becomes persistently activated in a genetically altered cell, it can promote the expansion of abnormal cell populations and disrupt the architecture of the tissue. The DKFZ and HI-STEM researchers found that, in the context of BRAF-mutant colorectal lesions, WNT activation helps initiate the transition from a premalignant state to a malignant tumor.

To follow this process, the investigators combined genetically engineered mouse models with three-dimensional intestinal organoids and single-cell analysis. Organoids are laboratory-grown structures derived from stem or tumor cells that reproduce several features of intestinal tissue, including aspects of its organization and response to signaling cues. Single-cell technologies allowed the researchers to examine gene activity in individual tumor and neighboring cells rather than averaging molecular signals across an entire tumor. This approach revealed that WNT activation was accompanied by extensive remodeling of the tumor microenvironment, the complex mixture of immune cells, connective-tissue cells, blood vessels, and signaling molecules that surrounds and influences cancer cells.

One of the most important changes involved CCL20, a chemokine that helps guide immune-cell movement. Chemokines are soluble signaling proteins that establish molecular gradients in tissues, effectively creating directional cues that immune cells can follow. CCL20 is recognized by the receptor CCR6 on certain immune-cell populations and can contribute to the recruitment and positioning of immune cells in epithelial tissues. In the models studied by the researchers, WNT-activated tumor cells produced markedly less CCL20 than their less transformed counterparts. The resulting reduction in chemokine signaling was associated with a decrease in immune-cell entry into the developing tumor.

This finding suggests that immune evasion begins during the earliest stages of malignant transformation rather than emerging only after a fully established tumor has developed. Instead of simply growing faster, the altered cells appear to modify the biological conditions around them. By weakening a signal that helps attract immune cells, they may reduce the likelihood that potentially cancer-fighting cells will encounter the emerging tumor. The result is not necessarily a complete absence of immune activity, but a tumor microenvironment with fewer immune cells and less effective immune surveillance. Such an environment can give genetically abnormal cells additional time to survive, multiply, and acquire further malignant properties.

The researchers also tested whether restoring the missing signal could influence tumor behavior. In experimental models, re-establishing CCL20 production significantly slowed tumor growth. This result supports the idea that the chemokine is not merely a passive marker of tumor development but may play a functional role in controlling the interaction between transformed cells and the immune system. It also demonstrates how a molecular change inside cancer cells can produce consequences at the level of the entire tissue. The study does not show that CCL20 restoration is ready for use as a treatment, but it identifies the signaling axis as a possible point of intervention for future research.

The work further connects two major features of BRAF-mutant colorectal cancer: abnormal growth signaling and immune escape. BRAF is part of the MAPK signaling cascade, a pathway that transmits signals controlling cell division and survival. WNT signaling operates through a separate but highly interconnected regulatory system, and cancer cells frequently exploit cooperation between these pathways. In the tumors examined in this study, WNT activity appears to provide the crucial step that drives BRAF-mutant precursor lesions toward malignancy while simultaneously altering their immune surroundings. This may help explain why tumors arising through the serrated pathway can behave differently from other forms of colorectal cancer, even when they develop in the same organ.

The findings point to WNT signaling as a potential therapeutic target, although significant obstacles remain. Several WNT-directed drugs are being evaluated in clinical development, but no WNT inhibitor has yet been approved as a cancer treatment. The pathway is essential for normal tissue maintenance, particularly in the intestine, raising concerns that systemic inhibition could damage healthy organs or produce unacceptable side effects. A more selective strategy might involve targeting abnormal WNT activity in tumors, interrupting cooperation between WNT and BRAF signaling, or combining WNT inhibition with immunotherapies. Restoring immune access to the tumor could, in principle, make cancer cells more visible or vulnerable to immune-based treatments, but this possibility must be tested in carefully designed preclinical and clinical studies.

The study provides a mechanistic explanation for how BRAF-mutated colorectal tumors may establish an immune-suppressed environment while they are still forming. It also illustrates the value of studying cancer as an evolving ecosystem rather than as a collection of isolated mutations. The researchers emphasize that the relationship between genetic alterations and immune function is central to understanding tumor aggressiveness. By showing that WNT-driven suppression of CCL20 can promote malignant transformation, the work offers a new framework for investigating serrated colorectal cancer and may eventually support combination treatments designed to target both the cancer cell’s growth circuitry and the immune environment that allows it to thrive.

Subject of Research: WNT-driven immune evasion and malignant transformation in BRAF-mutant colorectal cancer.

Article Title: WNT-driven immune evasion promotes malignant transformation of BRAF-mutant colorectal cancer.

Web References: https://doi.org/10.1053/j.gastro.2026.07.035

References: Manuel Mastel, Aitana Guiseris Martinez, Umberto Pozza, Jasmin Meier, Ioannis Chiotakakos, Sandra Jaun, Carolin Artmann, Gabriele Diamante, Nikolaos Georgakopoulos, Philipp Albrecht, Yvonne Petersen, Saskia Reuter, Barbara Schmitt, Michael Günther, Alexandra Thiran, Istiffa Nurfauziah, Ian Ghezzi, Kyanna S. Ouyang, Michael D. Milsom, Jens Puschhof, Nic G. Reitsam, Kim E. Boonekamp, Johannes Betge, Steffen Ormanns, Michael Boutros and Rene Jackstadt. “WNT-driven immune evasion promotes malignant transformation of BRAF-mutant colorectal cancer.” Gastroenterology, 2026. DOI: 10.1053/j.gastro.2026.07.035.

Keywords: colorectal cancer, BRAF mutation, WNT signaling, immune evasion, CCL20, tumor microenvironment, serrated lesions, cancer immunology, organoids, single-cell analysis, malignant transformation, colorectal cancer therapy